News

Press Releases

Proclara Biosciences Announces Initiation of NPT189 Clinical Development for Systemic Amyloidoses and Provides Pipeline Update
July 26, 2018

Proclara Biosciences Presents Preclinical Data Supporting the Development of GAIM-Based Therapies for Peripheral Amyloidoses at the 16th International Symposium on Amyloidosis
March 28, 2018

Proclara Biosciences to Present at the Cowen and Company 38th Annual Health Care Conference
March 6, 2018
 

Proclara Biosciences Strengthens Leadership Team with Appointment of David Michelson, M.D., as Chief Medical Officer
January 3, 2018
 

Proclara Biosciences Presents New Preclinical Data Supporting Development of GAIM-Based Therapies at Society for Neuroscience Annual Meeting
November 14, 2017

Proclara Biosciences to Present at the Stifel 2017 Healthcare Conference
November 7, 2017

Proclara Biosciences to Participate in Mizuho Biotechnology Conference 2017: CNS “Deep Management” Day
September 12, 2017

Proclara Biosciences  Presents New Preclinical Data Supporting the Development of NPT189 at Alzheimer’s Association International Conference (AAIC) 2017 
July 18, 2017

Proclara Biosciences Announces Pipeline Progress
July 17, 2017

Proclara Biosciences Appoints Suzanne Bruhn, Ph.D., as Chief Executive Officer to Guide Development of Novel Approach for Neurodegenerative Diseases  
April 26, 2017

Proclara Biosciences Australia, a subsidiary of Proclara Biosciences, awarded grant by Biopharmaceuticals Australia to help develop new biotherapy with blockbuster potential
March 10, 2017

Proclara Biosciences to Present at Cowen and Company 37th Annual Health Care Conference
March 1, 2017

Proclara Biosciences to Present at 28th Annual Piper Jaffray Healthcare Conference
November 23, 2016

Proclara Biosciences Awarded Part the Cloud Grant from Alzheimer’s Association to Support Development of NPT088 for Alzheimer’s Disease
November 18, 2016

Proclara Biosciences Announces Newly Issued U.S. Patents for its Core Technology Targeting Protein Misfolding Disorders
November 16, 2016

Proclara Biosciences Announces $47 Million in New Investment to Support the Development of Product Candidates in Alzheimer’s, Parkinson’s and Other Diseases
September 07, 2016

Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer’s Disease
September 07, 2016
 

Note: prior to September, 2016, Proclara Biosciences was known as NeuroPhage Pharmaceuticals.

 

NeuroPhage’s NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer’s Association International Conference
July 19, 2015

NeuroPhage to be Featured in Oral Session at the 2015 Alzheimer’s Association International Conference
July 13, 2015

NeuroPhage to Participate on Neuroscience Drug Development Panel at MassBio Annual Meeting March 27, 2015
March 20, 2015

NeuroPhage to Present at 12th International Conference on Alzheimer’s & Parkinson’s Diseases
March 16, 2015

NeuroPhage Expands Series D Financing to $27 Million
January 14, 2015

In the News

At CTAD, Tau PET Emerges as Favored Outcome Biomarker for Trials
Alzforum
December 8, 2017

Targeting toxic proteins: Novel drug approaches to defeat dementias
Patricia F. Fitzpatrick Dimond, GEN
December 2, 2016

New clues to target Alzheimer’s found in proteins
Shirley S. Wang, Wall Street Journal
July 20, 2015

Alzheimer’s drugs in the works might treat other diseases, too
Jon Hamilton, NPR
July 22, 2015

Universal plaque-busting drug could treat various brain diseases
Andy Coghlan, New Scientist
July 11, 2015

The bright side of Parkinson’s
Jon Palfreman, New York Times
February 21, 2015